ENVB

Enveric Biosciences, Inc. NASDAQ Listed May 4, 2015

Healthcare ·Biotechnology ·US · enveric.com

$1.42

+10.94% vs $1.28

Mkt Cap $475.3K

52w Low $1.28 0.9% of range 52w High $17.40

50d MA $2.52 200d MA $4.30

P/E (TTM) —

EV/EBITDA —

P/B 0.1x

Debt/Equity 0.0x

ROE -210.0%

P/FCF -0.1x

RSI (14) 29.30

ATR (14) $0.15

Beta 0.33

50d MA $2.52

200d MA $4.30

Avg Volume 217.3K

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

SIC Code

2834

CIK (SEC)

890821

Phone

239 302 1707

4851 Tamiami Trail North · Naples, FL 34103 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 27, 2026	AMC	-55.80	0.85	+101.5%	1.88	-3.2%	-4.8%	+8.4%	+10.3%	-5.1%	-2.0%	—
Nov 14, 2025	AMC	-63.00	-10.81	+82.8%	5.28	-0.6%	-5.9%	+14.1%	+3.0%	+0.2%	+2.1%	—
Aug 14, 2025	AMC	-63.00	-11.64	+81.5%	13.32	+0.0%	-0.9%	+8.2%	-4.2%	+1.8%	+0.0%	—
May 14, 2025	AMC	-6.00	-1.22	+79.7%	15.72	+0.0%	-3.8%	+3.2%	+4.6%	-0.7%	-8.1%	—
Mar 31, 2025	AMC	-3.45	-21.89	-534.5%	16.68	-2.2%	-5.8%	+3.8%	-5.9%	-5.5%	-5.0%	—
Nov 14, 2024	AMC	-7.80	-3.60	+53.8%	71.52	-4.0%	-8.1%	-3.3%	+0.6%	-1.5%	-3.8%	—
Aug 12, 2024	AMC	-8.25	-3.75	+54.5%	94.44	+6.7%	+1.4%	-7.9%	-1.4%	+1.7%	+2.6%	—
May 14, 2024	AMC	-9.15	-9.15	+0.0%	147.72	-0.6%	-4.0%	+14.2%	-6.7%	-2.2%	+0.8%	—
Mar 25, 2024	AMC	-23.24	-21.89	+5.8%	189.00	-1.0%	+1.0%	-3.8%	-2.0%	-11.0%	+28.1%	—
Nov 13, 2023	AMC	-28.94	-19.49	+32.7%	273.60	-2.6%	-1.3%	-5.0%	+1.0%	+4.2%	-2.7%	—
Aug 14, 2023	AMC	-0.65	-45.58	-6912.3%	482.40	-2.2%	-11.2%	-5.5%	-2.2%	-2.3%	+7.4%	—
Jun 8, 2023	AMC	—	-6.76	—	732.60	-0.2%	-6.6%	-2.4%	+4.6%	-6.2%	+6.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.20	$24.24	-3.8%	-8.6%	-5.2%	-5.5%	-1.2%	-5.3%
Jun 1	Alliance Global Partners	Maintains	Buy → Buy	—	$1779.36	$1890.00	+6.2%	+6.2%	+2.6%	-1.1%	-2.7%	+4.9%
Mar 8	Aegis Capital	Downgrade	Buy → Hold	—	$2251.80	$2250.00	-0.1%	+5.9%	+4.3%	+3.0%	-2.3%	-6.5%
Jul 8	Aegis Capital	Maintains	Buy → Buy	—	$18720.00	$18630.00	-0.5%	+10.1%	+1.7%	-0.9%	-3.9%	-4.1%
Jun 28	Maxim Group	Maintains	Buy → Buy	—	$19530.00	$21330.00	+9.2%	+19.8%	-5.8%	-2.9%	-3.4%	-4.8%

Institutional (13F) — Top 4 All ↗

#	Manager	Shares	Value	Chg	Period
1	Citigroup Inc	2,276	$8K	New	Dec 2025
2	Ubs Group Ag	3,612	$7K	Added	Mar 2026
3	Wells Fargo & Company/mn	1	$2	New	Mar 2026
4	Danske Bank A/s	1	$2	—	Mar 2026

Mutual Funds / ETFs (N-PORT) — Top 4 All ↗

#	Fund	Shares	Value	Period
1	AdvisorShares Psychedelics ETF	16,974	$33K	Mar 2026
2	Fidelity Extended Market Index Fund	6,968	$16K	Feb 2026
3	Fidelity Nasdaq Composite Index Fund	911	$2K	Feb 2026
4	Fidelity Series Total Market Index Fund	388	$912	Feb 2026

Data updated apr 25, 2026 7:17am · Source: financialmodelingprep.com